Answer
By Arun AgrahriLast reviewed
Short answer
Fewer heart attacks and strokes, possibly apart from weight loss, but there is too little counted evidence to be sure. The one counted source, a semaglutide trial as described on tape, saw much of that gap open before people had lost much weight. Precis has not read the trial itself.
GLP-1 drugs are worth taking for people with obesity.
The verdict on GLP-1 Agonists overall. 18 sources: 6 positive, 9 partly, 3 negative
positive partly neutral negative Each researcher and each study counts once per claim, however often they come up.
GLP-1 drugs cut cardiovascular events partly independent of weight loss.
2 sources: 2 positive. Fewer than 3 sources so far.
Researchers say
No researcher counted yet.
Studies show
2 positive
1 paper we read · 1 cited on tape, not yet checked against the paper
SELECT, cited on Huberman Lab, at 1:28:22
Positive Study
Open the tape at 1:28:22 →“was really surprising was a lot of that seemed to happen before the people even lose weight lost weight”
Controlled trial, N Engl J Med, 2023, PMID 37952131
Positive Study
Read the paper on PubMed →However, the data are consistent with the between-group difference in the incidence of cardiovascular disease emerging early in this trial, which suggests that more rapid treatment-induced physiological changes beyond the magnitude of body-weight loss may have mediated at least part of the cardiovascular benefit.
SELECT, cited on Huberman Lab, at 1:28:22 Study · positive
“was really surprising was a lot of that seemed to happen before the people even lose weight lost weight”
Controlled trial, N Engl J Med, 2023, PMID 37952131 Study · positive
However, the data are consistent with the between-group difference in the incidence of cardiovascular disease emerging early in this trial, which suggests that more rapid treatment-induced physiological changes beyond the magnitude of body-weight loss may have mediated at least part of the cardiovascular benefit.
Precis is not affiliated with or endorsed by YouTube or by any researcher, show or publisher we quote. We take no sponsorship, ad or affiliate money, and every verdict is our own review of what was said. How we stay independent
The only counted source here is a large semaglutide trial, as Zachary Knight describes it as a guest on Andrew Huberman's show. Precis has not read the trial itself, so this rests on his account. Four other mentions sit on the claim without being counted, because their origin or stance was unclear.
Knight says the trial cut heart attacks, strokes and deaths from heart causes, as expected. The surprise was the timing. The drug and placebo groups already differed before the people on the drug had lost much weight.
He adds that how much weight people lost did not track how well they were protected. One idea he describes is that the drugs calm inflammation through the inflammatory reflex, a loop that runs from the vagus nerve to the brainstem and back to the body. He presents that as an idea that is still emerging.
Anna Lembke, a guest on Peter Attia's show, describes rarely giving semaglutide off label to patients whose alcohol use disorder had resisted everything else. In one patient, she says, alcohol craving stopped completely. That is one case, and it is not counted here.
Ben Bikman, a guest on Rhonda Patrick's show, cites a newly published paper linking high-dose GLP-1 use to a higher risk of blindness. He stresses that the link is correlational and that he cannot say the drug causes it. He also cites data in which people on the higher weight-loss dose had more diagnosed major depression and suicidal behavior.
Mark Hyman, on his own show, argues against taking a GLP-1 for longevity. Among the side effects that concern him he lists gastroparesis (a stomach that stops emptying), bowel obstruction and pancreatitis, and he warns that much of the weight lost is muscle. He also says he is not against the drug for the right patient.
Neither Bikman's nor Hyman's remarks are counted toward this claim.
No counted source shows that a GLP-1 slows aging itself. If you take one or are weighing it, go over these risks with your prescriber.
Precis membership
The answer above is the whole answer: the verdict, every counted mention, where the sources disagree, and the receipt behind each one. Nothing on this page is held back.
A free account adds
Pro adds
Full GLP-1 Agonists evidence report
The verdict on every claim, and where the sources disagree